These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 8843954)
1. Serum tumor markers in chronic liver disease. Kadayifci A; Simsek H; Savas MC; Toppare M Neoplasma; 1996; 43(1):17-21. PubMed ID: 8843954 [TBL] [Abstract][Full Text] [Related]
2. The use of tissue polypeptide specific antigen as a marker in liver diseases. Cetin T; Oğuz A; Algan P; Yildirim IS Turk J Gastroenterol; 2003 Sep; 14(3):177-80. PubMed ID: 14655061 [TBL] [Abstract][Full Text] [Related]
3. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis, and its relationship with circulating thrombocyte counts. Koruk M; Onuk MD; Akçay F; Savas MC Hepatogastroenterology; 2002; 49(48):1645-8. PubMed ID: 12397754 [TBL] [Abstract][Full Text] [Related]
4. [Occurrence of increased alpha-fetoprotein in non-neoplastic hepatopathies of alcoholic or non-alcoholic origin]. Pol S; Nalpas B; Bezeaud A; Bréchot C; Berthelot P Gastroenterol Clin Biol; 1986 Feb; 10(2):112-6. PubMed ID: 2422087 [TBL] [Abstract][Full Text] [Related]
5. Serum levels of CA 50 in nonmalignant liver diseases: a clinical and biochemical study. Collazos J; Genolla J; Ruibal A Am J Gastroenterol; 1993 Mar; 88(3):409-12. PubMed ID: 8438849 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma. Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803 [TBL] [Abstract][Full Text] [Related]
7. The importance of serum and ascites fluid alpha-fetoprotein, carcinoembryonic antigen, CA 19-9, and CA 15-3 levels in differential diagnosis of ascites etiology. Sari R; Yildirim B; Sevinc A; Bahceci F; Hilmioglu F Hepatogastroenterology; 2001; 48(42):1616-21. PubMed ID: 11813585 [TBL] [Abstract][Full Text] [Related]
8. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961 [TBL] [Abstract][Full Text] [Related]
9. Measurement of tumor markers in chronic hemodialysis patients. Tzitzikos G; Saridi M; Filippopoulou T; Makri A; Goulioti A; Stavropoulos T; Stamatiou K Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):50-3. PubMed ID: 20061692 [TBL] [Abstract][Full Text] [Related]
10. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Cicognani C; Malavolti M; Morselli-Labate AM; Zamboni L; Sama C; Barbara L Arch Intern Med; 1997 Apr; 157(7):792-6. PubMed ID: 9125012 [TBL] [Abstract][Full Text] [Related]
11. [Decrease of haptoglobin serum level in patients with chronic viral hepatitis C]. Bacq Y; Schillio Y; Brechot JF; De Muret A; Dubois F; Metman EH Gastroenterol Clin Biol; 1993; 17(5):364-9. PubMed ID: 8349072 [TBL] [Abstract][Full Text] [Related]
12. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Marrero JA; Su GL; Wei W; Emick D; Conjeevaram HS; Fontana RJ; Lok AS Hepatology; 2003 May; 37(5):1114-21. PubMed ID: 12717392 [TBL] [Abstract][Full Text] [Related]
13. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758 [TBL] [Abstract][Full Text] [Related]
14. Abnormal serum tumour markers values do not imply the presence of extra-hepatic malignancies in patients with chronic liver disease. Puoti C; Bellis L; Guarisco R Dig Liver Dis; 2010 May; 42(5):387. PubMed ID: 19181575 [No Abstract] [Full Text] [Related]
15. [Quantitative analysis of serum hyaluronic acid and its application in liver disease]. Qiang Y; Wang J; Sun W Zhonghua Yu Fang Yi Xue Za Zhi; 1995 Jan; 29(1):21-3. PubMed ID: 7600884 [TBL] [Abstract][Full Text] [Related]
16. Influence of cardiopulmonary resuscitation on levels of tumour markers. Berent R; Auer J; Porodko M; Lamm G; Weber T; Wimmer E; Seier J; Aspöck G; Eber B Eur J Cancer Care (Engl); 2006 Jul; 15(3):252-6. PubMed ID: 16882121 [TBL] [Abstract][Full Text] [Related]
17. Squamous cell carcinoma antigen-immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Beneduce L; Castaldi F; Marino M; Quarta S; Ruvoletto M; Benvegnù L; Calabrese F; Gatta A; Pontisso P; Fassina G Cancer; 2005 Jun; 103(12):2558-65. PubMed ID: 15887222 [TBL] [Abstract][Full Text] [Related]
18. [Clinico-diagnostic significance of the determination of bile acids in chronic liver diseases]. Andreuzzi B; Vai C; Santese R; Andreuzzi P; Cantoni L Minerva Med; 1984 Mar; 75(13):749-56. PubMed ID: 6717831 [TBL] [Abstract][Full Text] [Related]
19. [A quantitative study of the relationship between levels of liver fibrosis markers in sera and fibrosis stages of liver tissues of patients with chronic hepatic diseases]. Ding XJ; Li SB; Li SZ; Liu HS; Liu B; Xu FM; Gu RW Zhonghua Gan Zang Bing Za Zhi; 2005 Dec; 13(12):911-4. PubMed ID: 16381637 [TBL] [Abstract][Full Text] [Related]
20. Serum xanthine oxidase in human liver disease. Battelli MG; Musiani S; Valgimigli M; Gramantieri L; Tomassoni F; Bolondi L; Stirpe F Am J Gastroenterol; 2001 Apr; 96(4):1194-9. PubMed ID: 11316169 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]